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Asian men. The extent of causality in these observations is yet to be determined, 
with further prospective cohort studies needed. Nevertheless, these findings high-
light the importance of properly managing patients with these risk factors to 
minimise the risk of fractures.
Muscular-skeletal DisorDers – cost studies
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estiMating the iMPact of exPanDing access to celecoxib for 
osteoarthritis Patients in china
Wang B.C.M.1, Xie X.P.2, Furnback W.1
1Alliance Life Sciences, Somerset, NJ, USA, 2Pfizer Inc., Beijing, China
Objectives: Currently in China, celecoxib is prescribed to patients with gastro-
intestinal bleeding or perforation history. The aim of this study was to model the 
effect of expanding access to all osteoarthritis (OA) patients in China. MethOds: 
We created a one-year budget impact model from a payer perspective comparing 
two scenarios. The first scenario (A) restricts the use of celecoxib to only patients 
with gastrointestinal bleeding or perforation history while the second scenario 
(B) does not restrict usage. In (A), patients were prescribed either diclofenac or 
celecoxib, but those prescribed celecoxib were only dispensed celecoxib if they 
had gastrointestinal bleeding or perforation history. Those prescribed celecoxib 
but not fitting the criteria were dispensed diclofenac. In (B), all prescriptions were 
dispensed as written. For both scenarios, celecoxib and diclofenac prescriptions 
were written 16.2% and 8% of the time, respectively. Patients with gastrointestinal 
bleeding or perforation history made up 5.58% of the OA population. Celecoxib was 
associated with a 20% copay while diclofenac did not have a copay. The base case 
scenario assumes 13,333 patients. Results: Going from (A) to (B), the total cost of 
celecoxib increased ¥2,679,866 (94.42%) while the total cost of diclofenac decreased 
¥1,817,170 (65.66%). The incremental total cost of drugs increased ¥862,697 (29.48%). 
The impact on a payer’s plans for the year was only due to drug costs since the 
cost to administer prior authorization was not considered. The per member per 
month increased ¥0.07 from ¥0.24 to ¥0.32. cOnclusiOns: The expanded access 
scenario (B) resulted in slightly higher drug costs to the payer, which may be accept-
able under most thresholds. Patient outcomes should also be considered to fully 
understand the impact of removing the gastrointestinal bleeding and perforation 
history stipulation.
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Prescribing Pattern anD cost analysis on (DMarD’s) Disease 
MoDifying anti rheuMatoiD Drugs in rheuMatoiD arthritis Patients 
of a tertiary care teaching hosPital in south inDia – a cross 
sectional stuDy
Tummeti  V.V.V.
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Objectives: To study the current prescription pattern and to analyze the cost 
of the treatment prescribed to RA patients referred to orthopedics OPD in a ter-
tiary care teaching hospital of South India. MethOds: The study protocol was 
approved by the institutional ethics committee. Patients attending Orthopedic OPD 
for existing RA disease were recruited as per inclusion criteria. Written informed 
consent was sought. Total 100 consecutive rheumatoid arthritis patients (fulfilling 
the American College of Rheumatology Criteria 1987) were recruited during study 
period. Study Design: Cross-sectional study. Study Duration: 06 Months (From July 
1st to December 31st 2014) Study Site: Department of Orthopedics, Government 
Medical College and Hospital, Anantapuramu, Andhra Pradesh, India. Results: 
Majority of patients (67%) in the study population were on combination of two 
DMARDs. Most frequently prescribed two DMARDs combination was methotrexate 
and hydroxychloroquine (64%). Average total cost per prescription was found to be 
763.39, while average hospital and out of pocket expense were 281.12 and 482.88 
respectively. cOnclusiOns: The drug use pattern in RA was found to be DMARDs 
based and majority of the cost was borne by the patient. The total increase in cost 
was due to administration of drugs to treat the adverse drug reaction. Prospective 
studies in a larger number of patients are needed to assess the utility of prescription 
audit and cost analysis of drugs used in RA.
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the costs of Major anD Minor cycling acciDents in tasMania, 
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Palmer A.J., Si L., Gordon J.
University of Tasmania, Hobart, Australia
Objectives: To estimate the societal costs of cycling accidents in Tasmania, 
Australia. MethOds: Between July 2011 and March 2012, 136 regular cyclists 
completed a telephone-based questionnaire. Information collected included 
demographics, cycling habits and details of major (requiring medical treatment 
or days off work) and minor (not requiring medical treatment or whole days off 
work) cycling accidents. The societal costs of accidents in 2011 Australian Dollars 
($) were estimated from self-reported medical resource consumption and lost work 
and leisure time, combined with published medical resource unit costs and sal-
ary data. Results: Participants reported 59 major accidents in 5 years preceding 
the interview, and 27 minor accidents in the previous 12 months. The mean total 
costs per major accident were $12,158, including direct medical costs $2,228, direct 
non-medical costs $372, resulted in 3.7 days off work equating to indirect costs of 
$6,027 and 54.5 days of lost leisure time equivalent to $3,531. The average costs of 
a minor accident were $632 and included direct non-medical costs of $225, pro-
ductivity losses of $117 and 5.2 days of lost leisure time valued at $290. The total 
annual costs to society of major cycling accidents in Tasmania were estimated 
at $4,123,445. cOnclusiOns: Costs resulting from both minor and major cycling 
accidents are substantial. The costs of improvements to cycling infrastructure/safety 
may be offset by reduced costs to society of cycling accidents.
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Objectives: To observe the effect of Iguratimod (T-614) on peripheral blood mon-
onuclear cells (PBMCs),Th1 cells and the expression level of IL-8 of rheumatoid 
arthritis (RA) patients, and to explore the possible mechanism of T-614 in treat-
ing RA. MethOds: 6 patients were diagnosed with RA referred to Department of 
Rheumatology, The Fifth Hospital of Xi’an. They were evaluated by the score of VAS, 
DAS28 and the response rates of ACR20/70, respectively. PBMC were prepared from 
6 patients in active stage of RA. and treated with T-614 at different concentration 
(lower dose: 100ug/ml; Higher dose: 1mg/ml ) for 1h and 24h. Flow cytometry (FCM) 
were performed to examine the apoptosis of PBMC and the level of IFN-γ secre-
tion by T cells. Results: We found that: We found that: 1) Iguratimod effectively 
induced apoptosis in PBMCs in 1h treatment, T-614 100ug/ml was 19.3±2.8% and 
1mg/ml 26.4±3.1%,(P< 0.05); 2) Compared with control, Iguratimod effectively inhibit 
CD3+ T cell secretion at 24h, T-641(1mg/ml) 1.33±0.12% and control (without T-614) 
2.91±0.13% P< 0.05). 3) Levels of IL-8 in the supernatant of T-614 treated group and 
control group were tested by ELISA, Iguratimod effectively inhibit IL-8 prodcution 
and there were significant differences (P< 0.05). cOnclusiOns: The results suggest 
that T-614 induced PBMC apoptosis and decreasing CD3+ T cell IFN-γ production 
and secretion of IL-8 in peripheral blood might be the possible mechanism of the 
effective of T-614 in treatment of RA.
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encuMberance to the treatMent of osteoPorosis: Physicians anD 
Patient PercePtion
Bhattacharya D.S., Salkar M.H., Majumdar A.
Bombay College of Pharmacy, Mumbai, India
Objectives: The objective of this pilot study was to assess the barriers to the 
treatment of Osteoporosis in post-menopausal women, from both a physician and 
patient perspective. MethOds: An open-ended structured survey was conducted 
for Physicians and patients across suburban areas of Mumbai. Questionnaires were 
designed to have questions on incidence of fractures, assessment methods for treat-
ment, treatment regimen, for physicians, and history of fractures and compliance 
to treatment for patients, identified thorough review of the literature. Descriptive 
statistics were performed. Results: As Reported by the Physicians ,85% of the post-
menopausal women had vitamin D deficiency, High Incidence of Bone Fracture (hip) 
were common among 70%of Patients, Preferred Regimen was Calcium Supplement 
(Dietary, Oral dose 500mg twice daily), Multivitamins and/or Bisphosphonates 
with Vitamin D (70mg/5,600U tablet Once weekly). Obstacle to treatment were 
Unavailability of Dual energy X-ray absorptiometry (DEXA) Technology which is 
Gold standard for diagnosing osteoporosis was perceived by 80% of physicians to be 
a barrier for Proper diagnosis. Patients advised for DEXA scan were Non-Compliant 
due to Cost of Diagnosis. Time and Cost of Diagnosing and Patient Reluctance were 
reported by Physicians .Major Reason for Non-Compliance were Cost of Therapy 
as Bisphosphonates are costly compared to vitamin D and calcium as it being not 
included under DPCO along with Poor Patient Counselling. cOnclusiOns: The 
survey gives preliminary evidences that Post-Menopausal Women were Vitamin D 
deficient. Unavailability of DEXA for diagnosis was perceived to be a major barrier 
for treatment .Increased cost of therapy and non-compliance could be undertaken 
by Government initiative to consider Bisphosphonates under DPCO and Provide 
DEXA machines in Hospitals for Free scan. Pharmacist can bridge the gap for poor 
Patient Counselling by educating the patient about importance of Adherence to 
Treatment and Occasional DEXA scan to be done for better monitoring of Bone 
loss/Recovery during Regimen.
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Objectives: The prevalence of both lifestyle-related metabolic disorders and 
osteoporosis is increasing in Asia. The aim of this systematic review was to sum-
marise all published studies within Asia on the association between disorders of 
glucose and fat metabolism (type 2 diabetes, hyperglycemia, hypercholesterolemia, 
hyperlipidemia, dyslipidemia, metabolic syndrome (MetS) and atherosclerosis) 
and risk of fracture and osteoporosis. The relationship between metabolic dis-
orders and bone mineral density (BMD) was also examined. MethOds: EMBASE 
(including MEDLINE) and the Cochrane Library were searched. Only studies con-
ducted within Asia (including East, South-East and South Asia and the Middle-
East), which reported multivariate analysis with a sample size ≥ 200 subjects, 
were included. Results: A total of 33 studies were included, of which 32 were 
assessed as adequate and one high quality based on SIGN criteria. All seven studies 
examining diabetes and fracture found that subjects with diabetes had a higher 
risk of fracture compared with subjects without diabetes (risk estimate range: 
1.26 to 4.73). In contrast, no association was found between diabetes and BMD, 
although a high degree of heterogeneity was observed. Two studies found that 
subjects with atherosclerosis had higher risk of fracture (risk estimate range: 
1.10 to 2.52). Included studies consistently reported that MetS is likely associated 
with osteoporosis or decreased BMD in men but not women. There was limited 
evidence investigating lipid metabolism and hyperglycemia and risk of fracture 
or bone loss. cOnclusiOns: These findings suggest that diabetes is a risk factor 
for fracture in Asian populations. Atherosclerosis may also be associated with 
increased fractures in Asian populations, and MetS associated with bone loss in 
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the treatment of Dupuytren’s contracture (DC) inclusive of medical consultations, 
allied health care services, and loss of work hours in Australia. MethOds: A sur-
vey of Australian clinicians was performed to inform the estimation of health care 
resource use and productivity loss during the recovery phase. The survey was sent 
to 89 hand, orthopaedic and plastic surgeons responsible for the treatment of DC 
across Australia, with 19 completed surveys received giving a response rate of 21%. 
Local unit costs were applied to these estimates of resource use and productivity 
loss. Results: Results from the clinician survey indicated on average the following 
number of visits to health care professionals were required: 3.2 surgeon, 3.8 physio-
therapy, 5.6 occupational therapy, 0.4 home nurse and 0.4 general practitioner visits. 
Based on this data the resource requirements associated with fasciectomy during 
the recovery phase were estimated to be $862.18. Loss of productivity informed by 
the survey suggests 85% of patients in the workforce required time off work for an 
average of 15.6 days. Based on labour force participation rates by age and gender the 
average productivity loss was estimated to be 6.1 days at a mean cost of $1,147.18 
per patient treated. When considering both the direct health care costs and pro-
ductivity costs, it was estimated a total of $2009.36 was incurred per patient during 
the recovery phase following fasciectomy. cOnclusiOns: Fasciectomy for DC is 
associated with considerable rehabilitation, follow-up and loss of productivity costs 
which account for a sizable proportion (39%) of total fasciectomy costs.
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Objectives: The aim of the study was to determine the cost effectiveness of oste-
oporosis screening strategies in Chinese postmenopausal women. MethOds: A 
Markov model including first and second order Monte Carlo simulation was con-
structed using a lifetime horizon, from which cost effectiveness of osteoporosis 
screening strategies from age 65 were compared to that of no screening from the 
Chinese health care perspective. The screening strategies were 1) Osteoporosis Self-
Assessment Tool (OST) followed by dual-energy X-ray absorptiometry (DEXA), 2) 
quantitative ultrasound (QUS), and 3) DEXA. Patients were assumed to receive alen-
dronate if osteoporosis was detected or they experienced an osteoporosis-related 
fracture, and were rescreened every 5 years if osteoporosis was not detected. First 
order Monte-Carlo using trackers was used to record fracture history. Probabilistic 
sensitivity analysis was performed to account for parameter uncertainties. Input 
parameters, including age-specific osteoporosis prevalence, fracture probabilities 
and costs and mortality probabilities were retrieved from published Chinese data 
where available. Costs were presented in 2013 USD. Both costs and effectiveness 
were discounted at 3% annually. A willingness-to-pay (WTP) threshold of 20,000 
USD/quality adjusted life year (QALY) gained was used according to the China 
Guidelines for Pharmacoeconomic Evaluations. Results: All screening strate-
gies were more effective than no screening, but were more costly. Compared to no 
screening, the incremental cost-effectiveness ratio (ICER) for screening with OST 
followed by DEXA from age 65 was $21,107/QALY gained. ICER for QUS screening was 
$9,756/QALY gained. ICER for DEXA screening was $8,527/QALY gained. Compared 
to DEXA alone, OST followed by DEXA and QUS screenings were dominated. Given a 
WTP threshold of $20,000/QALY gained, screening with DEXA alone had a probability 
of 56% being cost effective. cOnclusiOns: Based on incremental cost-effectiveness 
analysis, DEXA screening alone every 5 years from the age of 65 is recommended 
for osteoporosis screening in a Chinese setting.
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cost-effectiveness of DenosuMab vs. branD or generic zoleDronic 
aciD in Patients with breast cancer in kazakhstan
Bektur C., Nurgozhin T.
Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan
Objectives: Denosumab is recomended for preventing skeletal-related events 
(SREs) in adults with bone metastases from breast cancer (BC). Since recently generic 
zoledronic acid (ZA) became available, the aim of present study was to access the 
cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs 
in Kazakhstani patients with BC. MethOds: An excel-based Markov model was 
constructed with 4-week model cycles to analyse the cost-effectiveness of the treat-
ments from the perspective of Ministry of Health with a 10-year time horison for 
BC cohort. Direct costs (in 2014 tenge) included costs of drug, adverse event and 
SRE(pathologic fracture, surgery to bone, radiation to bone, spinal cord compression) 
treatment. A discount rate of 3% per year was applied for all costs. Effectiveness was 
appraised based on the number of SREs. The health states were defined according 
to SRE occurance,SRE history and death. The model assumed that a maximum of 1 
SRE could occur in each cycle. Transition probabilities were derived from the relevant 
phase III trials. Results were present in the incremental total cost per SRE avoided. 
One-way sensitivity analyses were performed to examine the robustness of the 
model. Results: Over 10-year period, denosumab incurred 1044 tenge lower costs 
than brand ZA, 568558 tenge higher costs than generic ZA, 1.28 fewer SREs per BC 
patient. The estimated incremental total direct costs per SRE avoided with the use 
of denosumab were -816 tenge (instead of brand ZA) and 444186 tenge (instead of 
generic ZA). Results were robust to one-way sensitivity analyses. cOnclusiOns: 
With assumption that brand and generic ZAs are equally effective in the prevention 
of SREs in BC patients, denosumab seems to be cost-effective alternative for brand 
ZA, and costly alternative for generic ZA from a perspective of Ministry of Health 
of Republic of Kazakhstan.
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aciD in Patients with Prostate cancer in kazakhstan
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intROductiOn: Leaving aside the difference in valuation of indirect costs of dis-
ease between various methods of estimating (human capital, friction cost method), 
the result of estimation of indirect costs may vary significantly in relation to other 
methodological decisions, such as the unit costs of work. Objectives: To show 
the variability of results obtained using various methods of indirect cost calcula-
tion illustrated with data from M2W study. MethOds: We have analyzed data on 
presenteeism and absenteeism measured with WPAI (Work Productivity and Activity 
Impairment) questionnaire from an observational, cross-sectional M2W study of 
patients with rheumatoid arthritis (RA), Crohn’s disease (CD) and psoriasis (Ps) in 
productive age in Poland (N= 814, 464 and 822, respectively). We estimated indirect 
costs of presenteeism and absenteeism of employed patients, using human capital 
method. We compared two methods of estimating unit costs of lost productivity 
recommended in the literature: the reflection of the productivity loss on GDP and 
market value of unit of work time. The loss of productivity was estimated as GDP 
per worker per hour at 51.04 PLN and was then multiplied by 0.65 to correct for the 
output elasticity of labor. The value of an hour of loss of productivity defined as the 
market value of work time was estimated using average hourly gross income in 
Poland (21.98 PLN). Results: Mean rate of overall productivity loss (presenteeism 
and absenteeism) for RA was 43%, for CD equaled 36% and for Ps 35%. Total annual 
costs of productivity lost due to RA, CD and Ps using work market value equaled 
1.03, 0.05 and 5.25 billion PLN respectively. Costs of lost productivity estimated using 
GDP amounted to 1.56, 0.08 and 7.92 billion PLN. cOnclusiOns: Depending on the 
theoretical assumptions for what constitutes the unit cost of productivity loss the 
results of indirect costs analysis show great variability.
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the econoMic cost of rheuMatoiD arthritis in taiwan
Chang J.Y., Lang H.C.
National Yang-Ming University, Taipei, Taiwan
Objectives: Rheumatoid arthritis (RA) is an autoimmune disease that results in 
a chronic, systemic inflammatory disorder. It can be a disabling and painful condi-
tion, which can lead to substantial loss of functioning and mobility if not adequately 
treated. The aim of this study was to estimate the economic cost of RA patients and 
their family in Taiwan. MethOds: We estimated cost of RA from the societal per-
spective. Data Sourced both from the Taiwan’s National Health Insurance Research 
Database (NHIRD) in 2010 and a face-to-face interview survey to the patients with 
RA. We identified all patients by both the primary diagnosis code ICD-9-CM 714.0 
and the catastrophic illness certificate from NHI claim data. In addition, Patients 
were recruited from rheumatology outpatient clinics at two medical centers and 
one regional hospital from March 2010 to June 2011. Direct medical costs, direct non-
medical costs, and productivity loss due to job loss and sick leave of patients with 
RA were estimated. Results: The mean annual per patient total medical costs were 
NT$177084. Drug expense represented more than half of the Medical costs. The mean 
annual direct nonmedical costs were NT$11195 per patient. Annual productivity loss 
due to job loss and sick leave were around NT$299635 per patient. cOnclusiOns: In 
this study, the indirect cost of RA is higher than the direct cost of RA in Taiwan. This 
result may represent that the government should make efforts not only to improve 
the treatment and care of RA patients but also to create a supportive and well social 
welfare environment for RA patients and their family.
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econoMic burDen of chilDhooD injury: a review
Wen L., Yang L.
Peking University, Beijing, China
Objectives: This study aims to summarize the results of the available evidence 
on economic burden of childhood injury in the world. MethOds: We summa-
rized Chinese literatures from CNKI and searched English studies from Pub-Med. 
“Children”, “Injury” and “burden ” as the initial search words identified in English. 
We selected articles with injury burden referring to economic burden and collected 
the major results of literatures on study design, methods of calculating economic 
burden. Results: We searched 34 literatures in Chinese and identified 33 articles 
in English, according to the inclusion criteria, 11 Chinese and 9 English articles were 
collected. We found that the result of each study was different in study design, cri-
teria of injury, children’s gender and age, injury types and the areas and periods of 
studies ,especially the method to calculate the economic burden of childhood injury. 
Researchers in China usually include only direct cost and sometimes indirect cost 
when calculating the economic burden, while scholars abroad usually cover direct, 
indirect cost of injury and sometimes intangible cost which caculating the cost of 
QALYs. cOnclusiOns: We got different results affected by types of injuries, charac-
teristics of population, regions of children and their social and economic situations. 
It’s necessary to build a unified way to calculate economic burden of children injury.
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health care resource requireMents anD costs During the 
recovery Phase of fasciectoMy for the treatMent of DuPuytren’s 
contracture: clinician survey
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1Thema Consulting, Sydney, Australia, 2THEMA Consulting Pty. Ltd., Sydney, Australia, 3Actelion 
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Objectives: The average inpatient procedural cost for fasciectomy in Australia is 
$3,079.57; however this does not capture the true cost of the surgery to the health 
care system or to society in total. This study sought to determine the extent and 
cost of health care resource use and productivity loss post-surgical fasciectomy for 
